Want to see IN:STAR full AI Analyst Report?
STAR Stock Chart & Stats
₹983.10
₹23.00(2.25%)
At close: 4:00 PM EDT
₹983.10
₹23.00(2.25%)
Day’s Range― - ―
52-Week Range₹769.60 - ₹1,231.45
Previous CloseN/A
Volume248.70K
Average Volume (3M)27.01K
Market Cap
₹97.55B
Enterprise Value₹102.30K
Total Cash (Recent Filing)₹2.13B
Total Debt (Recent Filing)₹17.58B
Price to Earnings (P/E)15.9
Beta0.88
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.42%
Share Statistics
EPS (TTM)60.35
Shares Outstanding92,172,714
10 Day Avg. Volume11,023
30 Day Avg. Volume27,012
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.78
Price to Sales (P/S)1.78
P/FCF Ratio71.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)68.3
Revenue Forecast (FY)₹56.72B
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability TurnaroundSteady revenue growth combined with a return to profitability indicates improving commercial execution and operating resilience. If sustained, the turnaround can strengthen internal funding capacity, support investment in the product pipeline, and create a more durable earnings base over the next several quarters.
Improving MarginsThe 2026 margin improvement shows that recent growth is translating into meaningful earnings rather than only higher sales. Stronger gross and net margins can improve reinvestment capacity and provide greater protection against competitive pricing pressure, provided the gains persist.
Lower Leverage And Rebounding ReturnsMaterial deleveraging and a recovery in return on equity represent a meaningful improvement in financial health and capital efficiency. Lower leverage should provide more flexibility for product development and commercialization, while stronger returns indicate that shareholder capital is being used more effectively.
Bears Say
Weak Free-Cash-Flow ConversionWeak conversion of accounting profit into free cash flow limits the cash available for debt reduction, research and development, and shareholder returns. The sharp 2026 decline also suggests that earnings quality remains uneven, making sustained self-funded growth less certain despite the profitability rebound.
Meaningful Residual DebtAlthough leverage has improved, the remaining debt still reduces financial flexibility and leaves the company more exposed to funding and repayment demands than a lightly levered peer. This can constrain capital allocation if operating performance weakens or cash conversion remains inconsistent.
Historical Earnings VolatilityThe recent profit recovery is encouraging, but the prior loss period demonstrates that earnings have not yet been consistently stable through the cycle. This history raises execution risk around maintaining margins and converting the latest improvement into durable profitability over the medium term.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹769.60 and its highest was ₹1231.45 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹97.55B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is Nov 04, 2026 which is in 57 days.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on Jul 31, 2026. The company reported ₹17 earnings per share for the quarter.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.42%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹17 in its last earnings report. Following the earnings report the stock price went down -4.226%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, India, and various other international markets. The company's operations are structured into two distinct segments: Pharmaceutical and Biopharmaceutical. It provides a diverse range of generic pharmaceuticals, available in multiple formats including tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Furthermore, Strides Pharma Science creates branded generic offerings for treating chronic ailments such as women's health issues, central nervous system disorders, cardiovascular conditions, diabetes, dermatological concerns, and probiotic support, marketed under brands like Renerve, Unibrol, Combiart, Duotab, and Vitafer. For institutional business, the company supplies drugs targeting infectious diseases, including anti-retrovirals, anti-malarials, anti-tuberculosis, and Hepatitis treatments. Incorporated in 1990, the company is headquartered in Bengaluru, India. It was formerly known as Strides Shasun Limited before adopting its current name in July 2018.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Piramal Pharma Limited
―
Sun Pharmaceutical Industries Limited
―